

Author Index (Vol. 82)

- Aalto-Setälä, K., see Hämäläinen, T. (82) 177
Abeywardena, M.Y., see Turner, J. (82) 105
Ågren, J.J., see Hessel, E. (82) 37
Albers, J.J., see Williams, P.T. (82) 53
Alessandri, C., see Violi, F. (82) 247
Arnon, R., see Raveh, D. (82) 19
Auget, J.L., see Chivot, L. (82) 205
- Bal, D.G., see Mozar, H.N. (82) 157
Balasubramaniam, S., Simons, L.A., Chang, S., Roach, P.D. and Nestel, P.J.
 On the mechanism by which an ACAT inhibitor (CL 277,082) influences plasma lipoproteins in the rat (82) 1
Balsano, F., see Violi, F. (82) 247
Banheri, C., see Spagnoli, L.G. (82) 27
Bard, J.M., see Chivot, L. (82) 205
Barter, P.J., see Newnham, H.H. (82) 167
Beaumont, J.L. and Vivier, P.
 Circulating IgA-Lp complexes in Watanabe heritable hyperlipidemic and cholesterol fed NZW rabbits (82) 227
Bigot, E., see Chivot, L. (82) 205
- Carlson, L.A., see Regnström, J. (82) 43
Carlson, L.A., see Tornvall, P. (82) 125
Carroll, K.K., see Samman, S. (82) 69
Chang, S., see Balasubramaniam, S. (82) 1
Charnock, J.S., see Turner, J. (82) 105
Chivot, L., Mainard, F., Bigot, E., Bard, J.M., Auget, J.L., Madec, Y. and Fruchart, J.C.
 Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E (82) 205
Cohn, S.D., see Genest, Jr., J.J. (82) 7
Cole, T.G., see Lo, G.S. (82) 59
Cordova, C., see Violi, F. (82) 247
- Devlin, S., see Newnham, H.H. (82) 167
Dresel, H.A., see Scheffler, E. (82) 261
Du, D.-Y., see Schwartzkopff, W. (82) 253
- Eisenberg, S., see Raveh, D. (82) 19
Erren, T., see Schneider, J. (82) 97
- Farag, S.A., see Mozar, H.N. (82) 157
Friedman, M.H.
 Some atherosclerosis may be a consequence of the normal adaptive vascular response to shear (82) 193
Frossard, P.M., see Genest, Jr., J.J. (82) 7
- Fruchart, J.C., see Chivot, L. (82) 205
Frühbis, J., see Scheffler, E. (82) 261
- Genest, Jr., J.J., Ordovas, J.M., McNamara, J.R., Robbins, A.M., Meade, T., Cohn, S.D., Salem, D.N., Wilson, P.W.F., Masharani, U., Frossard, P.M. and Schaefer, E.J.
 DNA polymorphisms of the apolipoprotein B gene in patients with premature coronary artery disease (82) 7
Ghiselli, A., see Violi, F. (82) 247
Grundy, S.M., see Jialal, I. (82) 185
Gutstein, W.H.
 The central nervous system and atherogenesis: role of the arterial smooth muscle cell (82) 145
- Hämäläinen, T., Palotie, A., Aalto-Setälä, K., Kontula, K. and Tikkanen, M.J.
 Absence of familial defective apolipoprotein B-100 in Finnish patients with elevated serum cholesterol (82) 177
Hamsten, A., see Tornvall, P. (82) 125
Han, C.-Z., see Schwartzkopff, W. (82) 253
Hänninen, A., see Hessel, E. (82) 37
Hänninen, O., see Hessel, E. (82) 37
Harris, W.S., see Inagaki, M. (82) 237
Helve, E., see Ojala, J.-P. (82) 85
Hessel, E., Ågren, J.J., Paulitschke, M., Hänninen, O., Hänninen, A. and Lerche, D.
 Freshwater fish diet affects lipid composition, deformability and aggregation properties of erythrocytes (82) 37
Hopkins, G.J., see Newnham, H.H. (82) 167
Huber, L., see Scheffler, E. (82) 261
- Inagaki, M. and Harris, W.S.
 Changes in lipoprotein composition in hypertriglyceridemic patients taking cholesterol-free fish oil supplements (82) 237
Israeli, A., see Raveh, D. (82) 19
Iuliano, L., see Violi, F. (82) 247
- Jialal, I., Vega, G.L. and Grundy, S.M.
 Physiologic levels of ascorbate inhibit the oxidative modification of low density lipoprotein (82) 185
- Kaffarnik, H., see Schneider, J. (82) 97
Kalantarov, G.F., see Shekhonin, B.V. (82) 213
Karjalainen, K., see Ojala, J.-P. (82) 85
Khosla, P., see Samman, S. (82) 69
Kitahara, M., Shinomiya, M., Shirai, K., Saito, Y. and Yoshida, S.

- Frequency and role of apo E phenotype in familial hypercholesterolemia and non-familial hyperlipidemia in the Japanese (82) 197
- Kontula, K., see Hämäläinen, T. (82) 177
- Koteliansky, V.E., see Shekhonin, B.V. (82) 213
- Krauss, R.M., see Williams, P.T. (82) 53
- Lerche, D., see Hessel, E. (82) 37
- Lithell, H., see Vessby, B. (82) 137
- Lo, G.S. and Cole, T.G.
- Soy cotyledon fiber products reduce plasma lipids (82) 59
- Madec, Y., see Chivot, L. (82) 205
- Mainard, F., see Chivot, L. (82) 205
- Masharani, U., see Genest, Jr., J.J. (82) 7
- Mauriello, A., see Spagnoli, L.G. (82) 27
- Mazurov, A.V., see Shekhonin, B.V. (82) 213
- McCully, K.S., see Olszewski, A.J. (82) 75
- McLennan, P.L., see Turner, J. (82) 105
- McNamara, J.R., see Genest, Jr., J.J. (82) 7
- Meade, T., see Genest, Jr., J.J. (82) 7
- Mitkevich, O.V., see Shekhonin, B.V. (82) 213
- Mozar, H.N., Bal, D.G. and Farag, S.A.
- The natural history of atherosclerosis: an ecologic perspective (82) 157
- Nestel, P.J., see Balasubramaniam, S. (82) 1
- Newby, A.C., see Southgate, K. (82) 113
- Newnham, H.H., Hopkins, G.J., Devlin, S. and Barter, P.J.
- Lipoprotein lipase prevents the hepatic lipase-induced reduction in particle size of high density lipoproteins during incubation of human plasma (82) 167
- Nilsson, J., see Regnström, J. (82) 43
- Ojala, J.-P., Helve, E., Karjalainen, K., Tarkkanen, A. and Tikkanen, M.J.
- Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up (82) 85
- Olszewski, A.J., Szostak, W.B. and McCully, K.S.
- Plasma glucosamine and galactosamine in ischemic heart disease (82) 75
- Ordovas, J.M., see Genest, Jr., J.J. (82) 7
- Orlandi, A., see Spagnoli, L.G. (82) 27
- Palmieri, G., see Spagnoli, L.G. (82) 27
- Palotie, A., see Hämäläinen, T. (82) 177
- Pasetto, N., see Spagnoli, L.G. (82) 27
- Paulitschke, M., see Hessel, E. (82) 37
- Pottins, I., see Schwartzkopff, W. (82) 253
- Pratico, D., see Violè, F. (82) 247
- Raveh, D., Israeli, A., Arnon, R. and Eisenberg, S.
- Effects of lovastatin therapy on LDL receptor activity in circulating monocytes and on structure and composition of plasma lipoproteins (82) 19
- Regnström, J., Walldius, G., Carlson, L.A. and Nilsson, J.
- Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro (82) 43
- Roach, P.D., see Balasubramaniam, S. (82) 1
- Robbins, A.M., see Genest, Jr., J.J. (82) 7
- Saito, Y., see Kitahara, M. (82) 197
- Salem, D.N., see Genest, Jr., J.J. (82) 7
- Samman, S., Khosla, P. and Carroll, K.K.
- Influence of dietary minerals on apolipoprotein B metabolism in rabbits fed semipurified diets containing casein (82) 69
- Samokhin, G.P., see Shekhonin, B.V. (82) 213
- Schaefer, E.J., see Genest, Jr., J.J. (82) 7
- Scheffler, E., Huber, L., Frühbis, J., Schulz, I., Ziegler, R. and Dresel, H.A.
- Alteration of plasma low density lipoprotein from smokers (82) 261
- Schleicher, J., see Schwartzkopff, W. (82) 253
- Schneider, J., Erren, T., Zöfel, P. and Kaffarnik, H.
- Metformin-induced changes in serum lipids, lipoproteins, and apoproteins in non-insulin-dependent diabetes mellitus (82) 97
- Schulz, I., see Scheffler, E. (82) 261
- Schwartzkopff, W., Schleicher, J., Pottins, I., Yu, S.-B., Han, C.-Z. and Du, D.-Y.
- Lipids, lipoproteins, apolipoproteins, and other risk factors in Chinese men and women with and without myocardial infarction (82) 253
- Shekhonin, B.V., Tararak, E.M., Samokhin, G.P., Mitkevich, O.V., Mazurov, A.V., Vinogradov, D.V., Vlasik, T.N., Kalantarov, G.F. and Koteliansky, V.E.
- Visualization of apo B, fibrinogen/fibrin, and fibronectin in the intima of normal human aorta and large arteries and during atherosclerosis (82) 213
- Shinomiya, M., see Kitahara, M. (82) 197
- Shirai, K., see Kitahara, M. (82) 197
- Simons, L.A., see Balasubramaniam, S. (82) 1
- Southgate, K. and Newby, A.C.
- Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP (82) 113
- Spagnoli, L.G., Palmieri, G., Mauriello, A., Orlandi, A., Bancheri, C. and Pasetto, N.
- High-dose synthetic progestogens inhibit foam and smooth muscle cell proliferation and atherosclerotic plaque formation in aortas of rabbits fed a hypercholesterolemic diet (82) 27
- Szostak, W.B., see Olszewski, A.J. (82) 75
- Tararak, E.M., see Shekhonin, B.V. (82) 213
- Tarkkanen, A., see Ojala, J.-P. (82) 85
- Tikkanen, M.J., see Hämäläinen, T. (82) 177
- Tikkanen, M.J., see Ojala, J.-P. (82) 85
- Tornvall, P., Hamsten, A. and Carlson, L.A.
- Abnormalities of composition and of in vitro lipolysis products of human small very low density lipoproteins in hypertriglyceridemia (82) 125

Turner, J., McLennan, P.L., Abeywardena, M.Y. and Char-
nock, J.S.

Absence of coronary or aortic atherosclerosis in rats having
dietary lipid modified vulnerability to cardiac arrhythmias
(82) 105

Vega, G.L., see Jialal, I. (82) 185

Vessby, B. and Lithell, H.

Interruption of long-term lipid-lowering treatment with be-
zafibrate in hypertriglyceridaemic patients. Effects on lipo-
protein composition, lipase activities and the plasma lipid
fatty acid spectrum (82) 137

Vinogradov, D.V., see Shekhonin, B.V. (82) 213

Violi, F., Pratico, D., Ghiselli, A., Alessandri, C., Iuliano, L.,
Cordova, C. and Balsano, F.

Inhibition of cyclooxygenase-independent platelet aggrega-
tion by low vitamin E concentration (82) 247

Vivier, P., see Beaumont, J.L. (82) 227

Vlasik, T.N., see Shekhonin, B.V. (82) 213

Walldius, G., see Regnström, J. (82) 43

Williams, P.T., Albers, J.J., Krauss, R.M. and Wood, P.D.S.

Associations of lecithin:cholesterol acyltransferase (LCAT)
mass concentrations with exercise, weight loss, and plasma
lipoprotein subfraction concentrations in men (82) 53

Wilson, P.W.F., see Genest, Jr., J.J. (82) 7


Wood, P.D.S., see Williams, P.T. (82) 53

Yoshida, S., see Kitahara, M. (82) 197

Yu, S.-B., see Schwartzkopff, W. (82) 253

Ziegler, R., see Scheffler, E. (82) 261

Zöfel, P., see Schneider, J. (82) 97



Subject Index (Vol. 82)

- ACAT inhibitor, (82) 1
Adaptive response, (82) 193
Antioxidants, (82) 185
Apo B, (82) 213
Apo E phenotype, (82) 197
Apolipoprotein, (82) 197
Apolipoprotein B, (82) 7
Apolipoprotein B-100, (82) 177
Apolipoprotein B metabolism, (82) 69
Apolipoproteins, (82) 253
Apolipoproteins A-I, B, C-III, E, (82) 205
Arabinogalactan, (82) 59
Arrhythmia, (82) 105
Arterial injury, (82) 145
Arterial smooth muscle cell proliferation, (82) 145
Artificial aggregation, (82) 37
Aspirin, (82) 247
Atherogenesis, (82) 145; (82) 227
Atherosclerosis, (82) 27; (82) 105; (82) 157; (82) 177; (82) 185; (82) 213; (82) 261
ATP concentration, (82) 113

Bezafibrate, (82) 137
8-Br-cAMP, 8-Br-cGMP, (82) 113

Casein, (82) 69
Cell growth, (82) 113
Cellulosic, (82) 59
Cholesterol, (82) 19; (82) 69; (82) 237
Cholesterol absorption, (82) 1
Cholesterol-feeding, (82) 227
Cholesteryl ester, (82) 261
Cholesteryl ester transfer protein, (82) 167
Chylomicrons, (82) 1
Circulating immune complexes, (82) 227
CNS, (82) 145
Colestipol, (82) 85
Combination therapy, (82) 85
Coronary artery, (82) 105
Coronary artery disease, (82) 7
Coronary bypass, (82) 205
Coronary heart disease, (82) 157
Deformability, (82) 37

Diabetes type II, (82) 97
Dietary fat, (82) 105
Docosahexaenoic acid, (82) 237
Drug treatment, (82) 85

Eicosapentaenoic acid, (82) 237
Epidemiology, (82) 253
Erythrocytes, (82) 37
Exercise, (82) 53

Familial hypercholesterolemia, (82) 197
Fatty acid composition, (82) 137
Fibrinogen/fibrin, (82) 213
Fibronectin, (82) 213
Fish oil, (82) 105; (82) 237
Fluid dynamic shear, (82) 193
Food chain, (82) 157

Galactosamine, (82) 75
Genetics, (82) 7
Geometry effects, (82) 193
Glucosamine, (82) 75
Glycoproteins, (82) 75
Glycosaminoglycans, (82) 75

HDL, (82) 1; (82) 237
HDL particle size, (82) 167
Height loss, (82) 53
Hepatic lipase, (82) 167
Homocysteine, (82) 75
Hypercholesterolemia, (82) 27; (82) 59; (82) 177
Hypercholesterolemic patients, (82) 43
Hypertriglyceridemia, (82) 59; (82) 125
Hypothalamic stimulation, (82) 145

IDL, (82) 197
IgA-Lp, (82) 227
Immunofluorescence, (82) 213
Inhibition, (82) 113
In vitro LDL, (82) 125
Ischemic heart disease, (82) 157

LDL, (82) 19; (82) 185; (82) 237; (82) 261
LDL receptor, (82) 19; (82) 43
Lecithin:cholesterol acyltransferase, (82) 53
Lipid lowering drugs, (82) 19
Lipid peroxidation, (82) 261
Lipids, (82) 205; (82) 253
Lipoprotein lipase, (82) 125; (82) 167
Lipoprotein metabolism, (82) 197
Lipoproteins, (82) 97; (82) 137; (82) 237; (82) 253
Logistic discriminant analysis, (82) 205
Long-term effects, (82) 85

Long-term treatment, (82) 137

Lovastatin, (82) 85

Lp(a), (82) 253

Macrophages, (82) 43; (82) 261

Medroxyprogesterone acetate, (82) 27

Men, (82) 53

Metformin, (82) 97

Minerals, (82) 69

Moderate freshwater fish diet, (82) 37

Myocardial infarction, (82) 253

Norethisterone, (82) 27

NZW rabbits, (82) 227

Oxidatively modified LDL, (82) 43

Plasma cholesterol, (82) 1

Plasma lipids, (82) 75

Plasma lipoprotein fraction, (82) 53

Plasma lipoproteins, (82) 69

Platelet aggregation, (82) 247

Polyunsaturated fatty acids, (82) 37; (82) 105

Primary hypercholesterolemia, (82) 85

Probuco, (82) 43

Progestogens, (82) 27

Rabbit aortic explants, (82) 113

Rabbits, (82) 69

Regulation, (82) 193

Restriction fragment-length polymorphisms (RFLP), (82) 7

Saturated fatty acids, (82) 105

Skeletal muscle lipoprotein lipase activity, (82) 137

Small VLDL, (82) 125

Smoking, (82) 261

Soy cotyledon fiber, (82) 59

Thromboxane A₂, (82) 247

Triglycerides, (82) 237

Vascular smooth muscle, (82) 113

Vasospasm, (82) 145

Viruses, (82) 157

Vitamin E, (82) 247; (82) 261

VLDL, (82) 197; (82) 237

VLDL composition, (82) 125

WHHL rabbits, (82) 227

Zonal centrifugation, (82) 19

